Therefore, whether it is possible to inhibit the downstream factors of NLRP3 inflammasome and its signaling pathways is expected to provide effective therapeutic options as well as new potential future targeted therapies for CAPS and other NRLP3-associated autoinflammatory diseases. The gene discussed is NLRP3; the disease is cryopyrin-associated periodic syndrome.